These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21993768)

  • 1. Solifenacin objectively decreases urinary sensation in women with overactive bladder syndrome.
    Lowenstein L; Kenton K; Mueller ER; Brubaker L; Sabo E; Durazo-Arivzu RA; Fitzgerald MP
    Int Urol Nephrol; 2012 Apr; 44(2):425-9. PubMed ID: 21993768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overactive bladder syndrome: what is the role of evidence of detrusor overactivity in the cystometric study?
    Vecchioli-Scaldazza C; Grinta R
    Minerva Urol Nefrol; 2010 Dec; 62(4):355-61. PubMed ID: 20944536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
    Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
    Urol Int; 2014; 93(4):470-3. PubMed ID: 25170796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.
    Hsiao SM; Lin HH; Kuo HC
    Neurourol Urodyn; 2014 Mar; 33(3):331-4. PubMed ID: 23494586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
    Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C
    Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder.
    Tanaka Y; Masumori N; Tsukamoto T
    Int J Urol; 2010 Sep; 17(9):796-800. PubMed ID: 20649825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.
    Brubaker L; FitzGerald MP
    Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jul; 18(7):737-41. PubMed ID: 17131169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes.
    Ohtake A; Sato S; Sasamata M; Miyata K
    J Pharmacol Sci; 2010; 112(2):135-41. PubMed ID: 20134114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study.
    Chung JH; Lee JY; Kang DH; Ha US; Lee SH; Ham WS; Cho KS; Han JH; Park J; Yoo TK; Lee SW
    Neurourol Urodyn; 2012 Sep; 31(7):1175-80. PubMed ID: 22674356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
    Swift SE; Siami P; Forero-Schwanhaeuser S
    Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
    Liu HT; Lin H; Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility of urodynamic filling sensation at weekly interval in healthy volunteers and in women with detrusor overactivity.
    Van Meel TD; Wyndaele JJ
    Neurourol Urodyn; 2011 Nov; 30(8):1586-90. PubMed ID: 21538500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
    Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
    BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg.
    Brunton S; Kuritzky L
    Curr Med Res Opin; 2005 Jan; 21(1):71-80. PubMed ID: 15881477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency.
    Han JY; Lee KS; Park WH; Park CH; Lee JG; Lee JZ; Kim DY; Na YG; Kwon DD; Choo MS
    PLoS One; 2014; 9(11):e112063. PubMed ID: 25401784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial.
    Aydoğmuş Y; Sunay M; Arslan H; Aydın A; Adiloğlu AK; Şahin H
    Urol Int; 2014; 93(4):437-43. PubMed ID: 25033919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.